Canopy Growth Corporation is a cannabis company. It delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.

Employees

960

Sector

Pharmaceuticals

Calendar

08-07 - Q1 2026 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
13/06/25	2.040 $	-3.32%	1,058,526
12/06/25	2.110 $	-2.31%	1,646,792
11/06/25	2.160 $	+4.35%	3,333,045
10/06/25	2.070 $	-5.91%	2,649,420
09/06/25	2.200 $	-4.76%	3,525,985

Delayed Quote Toronto S.E., June 13, 2025 at 09:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

2.040CAD

Average target price

2.872CAD

Spread / Average Target

+40.80%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Toronto S.E. Other stock markets 21:00:00 13/06/2025 BST			5-day change	1st Jan Change
2.040 ^CAD	-3.32%		-11.69%	-48.22%

06-06	Canopy Growth To Offer & Sell, From Time To Time, Up To 21.9 Million Common Shares By Selling Securityholders	RE
05-30	Canopy Growth Corporation, Q4 2025 Earnings Call, May 30, 2025

Capitalization	382M 282M 244M 229M 207M 24.25B 433M 2.67B 1.04B 11.1B 1.06B 1.03B 40.55B	P/E ratio 2026 *	-2.65x	P/E ratio 2027 *	-3.42x
Enterprise value	382M 282M 244M 229M 207M 24.25B 433M 2.67B 1.04B 11.1B 1.06B 1.03B 40.55B	EV / Sales 2026 *	1.38x	EV / Sales 2027 *	1.3x
Free-Float	71.49%	Yield 2026 *	-	Yield 2027 *	-

Canopy Growth To Offer & Sell, From Time To Time, Up To 21.9 Million Common Shares By Selling Securityholders	06-06	RE
Canopy Growth Corporation, Q4 2025 Earnings Call, May 30, 2025	05-30
Toronto Stocks Slip; Laurentian Bank of Canada Gains on 2Q Profit	05-30	DJ
Canopy Growth Q4 Loss Widens on Higher Expenses	05-30	MT
Canopy Growth Brief: Q4 Basic and Diluted Loss Per Share $1.43	05-30	MT
Canopy Growth Brief: Q4 Net Loss Attributable $220.788 Million	05-30	MT
Canopy Growth Brief: Q4 Net revenue $65.0 Million	05-30	MT
Canopy Growth Brief: Revenue Increased 4% in Q4 FY2025	05-30	MT
Canopy Growth Corporation Reports Earnings Results for the Full Year Ended March 31, 2025	05-30	CI
Canopy Growth Corporation Auditor Raises 'Going Concern' Doubt	05-29	CI
Canopy Growth Corporation Drives Innovation in High-Demand Segments with Latest Product Launches	05-06	CI
High just got higher: Trump tariffs to raise prices for US cannabis users	04-03	RE
Canopy Growth And Spectrum Therapeutics Announce Spectrum Reserve, A New Premium Medical Cannabis Brand	04-02	RE

Piper Sandler Adjusts Price Target on Canopy Growth to $2 From $3, Maintains Underweight Rating	09/07/24	MT
Canopy Growth Slides After Constellation Directors Leave, Share Conversion	19/04/24	DJ
Canopy Growth Price Target Raised to $0.50 at CIBC	31/10/23	MT
Piper Sandler Cuts Canopy Growth Price Target to US$1, Reiterates Underweight	02/05/23	MT
Piper Sandler Trims Canopy Growth Price Target to $1 From $2, Maintains Underweight Rating	02/05/23	MT

Canopy Growth Corporation Share Price

Equities

WEED

CA1380357048

Pharmaceuticals

Valuation: Canopy Growth Corporation

Chart: Canopy Growth Corporation

Latest news: Canopy Growth Corporation

Last Transcript: Canopy Growth Corporation

Analysts' recommendations: Canopy Growth Corporation

Press Releases: Canopy Growth Corporation

News in other languages: Canopy Growth Corporation

Quotes and Performance

Course Extremes

Managers and Directors: Canopy Growth Corporation

Alternative Medicine

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

CGC Investors Have Opportunity to Lead Canopy Growth Corporation Securities Fraud Lawsuit with the Schall Law Firm	06-03	BU
CGC Investors Have the Opportunity to Lead the Canopy Growth Securities Fraud Lawsuit with Faruqi & Faruqi, LLP	06-03	BU
Deadline Soon: Canopy Growth Corporation (CGC) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit	06-02	BU
Canopy Growth : Financial Statements (Q4 FY2025 FS FINAL)	06-02	PU
Canopy Growth : Management Discussion & Analysis (Q4 FY2025 MDA FINAL)	06-02	PU

MÄRKTE USA/Arbeitsmarktdaten und neue Zolldrohung sorgen für Verkäufe	02-07
En Direct des marchés : Pluie de résultats en Europe, Qualcomm brille aux Etats-Unis	11-07
Comme un air de déjà-vu	11-07
MÄRKTE USA/Leichter - Dow & Co mit Strohfeuer nach Fed-Kommentaren	01/05/24
MÄRKTE USA/Sorgen vor falkenhafter Fed bremsen weiter	01/05/24

1 day	-3.32%
1 week	-11.69%
Current month	+13.33%
1 month	+1.49%
3 months	+33.33%
6 months	-53.85%
Current year	-48.22%

1 week	1.99	2.46
1 month	1.62	2.75
Current year	1.08	4.41
1 year	1.08	11.89
3 years	1.08	64.4
5 years	1.08	716
10 years	1.08	766.8

Manager	Title	Age	Since
Luc Mongeau CEO	Chief Executive Officer	58	05/01/2025
Judy Hong DFI	Director of Finance/CFO	53	18/11/2021
Tyler Burns IRC	Investor Relations Contact	-	31/12/2015

Director	Title	Age	Since
Theresa Yanofsky BRD	Director/Board Member	68	30/03/2020
David Lazzarato CHM	Chairman	69	17/04/2024
Willy Kruh BRD	Director/Board Member	68	06/02/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
CANOPY GROWTH CORPORATION	-3.32%	-11.69%	-80.16%	-95.17%	282M
DONG-E-E-JIAO CO.,LTD.	+0.26%	-1.91%	-17.74%	+62.19%	4.82B
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.	-2.20%	+0.47%	-24.71%	-2.03%	3.53B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-1.43%	+0.35%	-15.78%	-34.06%	3.38B
TASLY PHARMACEUTICAL GROUP CO., LTD	-2.91%	-1.66%	+19.81%	+56.39%	3.34B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-1.54%	-1.89%	-4.65%	+40.92%	3.19B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-1.72%	+0.30%	+10.48%	-14.73%	2.44B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	-3.19%	-1.79%	-4.10%	+82.41%	1.85B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-2.27%	-1.84%	+18.11%	-3.80%	1.78B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	-3.04%	+1.06%	+12.84%	+101.05%	1.66B
Average	-2.14%	-0.01%	-8.59%	+19.32%	2.63B
Weighted average by Cap.	-1.75%	-1.38%	-4.80%	+28.45%

	2026 *	2027 *
Net sales	277M 204M 176M 165M 150M 17.55B 313M 1.93B 752M 8.03B 765M 749M 29.35B	294M 216M 187M 176M 159M 18.62B 332M 2.05B 798M 8.52B 812M 794M 31.14B
Net income	-106M -77.83M -67.33M -63.18M -57.25M -6.7B -120M -738M -287M -3.07B -292M -286M -11.21B	-96.32M -70.92M -61.35M -57.57M -52.17M -6.11B -109M -673M -262M -2.8B -266M -260M -10.21B
Net Debt	-	-